ENVB
Enveric Biosciences, Inc.
Key Financials
Net Income
$-8771987
↑ 8.4%
Revenue
$26.3M
N/A
Gross Profit
$8.2M
↓ 9.3%
Operating Income
$-8774448
↑ 8.9%
EPS (Diluted)
$-36.24
↓ 90.3%
Total Liabilities
$4.0M
↓ 9.5%
Total Assets
$5.1M
↑ 65.3%
Shareholders' Equity
$4.2M
↑ 162.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 6/9/2026 | View on SEC |
| 424B5 | 6/9/2026 | View on SEC |
| 8-K | 6/9/2026 | View on SEC |
| 4 | 6/3/2026 | View on SEC |
| 4 | 6/3/2026 | View on SEC |
| 4 | 6/3/2026 | View on SEC |
| 4 | 6/3/2026 | View on SEC |
| 4 | 6/3/2026 | View on SEC |
| 4 | 6/3/2026 | View on SEC |
| 4 | 6/3/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ENVB |
| Company Name | Enveric Biosciences, Inc. |
| CIK | 890821 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (617) 444-8400 |